

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete If Known

Application Number	10/716,175
Filing Date	11/18/2003
First Named Inventor	Dawei Chen et al.
Art Unit	1614
Examiner Name	C. Aulakh
Attorney Docket Number	API-0002

Sheet 1 of 6

U.S. PATENT DOCUMENTS

Examiner Initials ¹	Cite No.	Document Number Number ² Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CA	1.	3 966 968	06-29-1976	Andree et al.	
CA	2.	4 044 126	08-23-1977	Cook et al.	
CA	3.	4 350 706	09-21-1982	Brouwer et al.	
CA	4.	4 364 923	12-12-1982	Cook et al.	
CA	5.	4 414 209	11-08-1983	Cook et al.	
CA	6.	4 522 811	06-11-1985	Eppstein et al.	
CA	7.	4 868 215	09-19-1989	Bisabrie-rshadi et al.	
CA	8.	5 001 266	03-19-1991	Rigterink et al.	
CA	9.	5 114 918	05-19-1992	Ishikawa et al.	
CA	10.	5 166 180	11-24-1992	Jenkins	
CA	11.	5 266 707	11-30-1993	Matsumoto et al.	
CA	12.	5 268 389	12-07-1993	Harrison et al.	
CA	13.	5 344 842	09-06-1994	Missbach	
CA	14.	5 424 204	06-13-1995	Aoyama et al.	
CA	15.	5 437 996	08-01-1995	Kojiri et al.	
CA	16.	5 449 812	09-12-1995	Schnabel et al.	
CA	17.	5 589 365	12-31-1996	Kojiri et al.	
CA	18.	5 591 842	01-07-1997	Kojiri et al.	
CA	19.	5 656 642	08-12-1997	Fujioka et al.	
CA	20.	5 693 827	12-02-1997	Harrison et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No.	Document Number Office ² Number ³ Kind ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
CA	21	CA 2170222	08-28-1996	Bayer Aktiengesellschaft		
CA	22	EP 0 518 376 A1	12-16-1992	Canon Kabushiki Kaisha		
CA	23	EP 1 251 130 A1	10-23-2002	Kyowa Hakko Kogyo Co Ltd		
CA	24	JP 06-003787 A2	01-14-1994	Konica Corp	Transl. of Abstract	X
CA	25	JP 08-287171 A2	10-11-1994	Takeda Chem Ind. Ltd	Transl. of Abstract	X
CA	26	JP 11-335375 A2	12-07-1999	Mitsui Chem Inc	Machine translation	X
CA	27	WO 97/03976 A1	02-06-1997	Nissan Chemical Industries		
CA	28	WO 97/11050 A1	03-27-1997	UBE Industries Ltd	Transl. of claims only	X
CA	29	WO 97/30047 A1	08-21-1997	Agreva UK Limited		
CA	30	WO 98/42323 A1	10-01-1998	Takeda Chemical Industries		

Examiner
Signature

AULAKH

Date
Considered

3/27/06

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP-600. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/716,175
Filing Date	11/18/2003
First Named Inventor	Dawei Chen et al.
Art Unit	1614
Examiner Name	C. Aulakh
Attorney Docket Number	API-0002

Sheet 2 of 6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cita No.	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ^b (if known)			
CA	31.	5 723 409		03-03-1998	Schnabel et al.	
CA	32.	5 728 699		03-17-1998	Toriyabe et al.	
CA	33.	5 840 917		11-24-1998	Oi et al.	
CA	34.	5 849 666		12-15-1998	Kehne et al.	
CA	35.	5 874 615		02-23-1999	Verbrugge et al.	
CA	36.	5 922 740		07-13-1999	Braunlich et al.	
CA	37.	6 133 258		10-17-2000	Shishikura et al.	
CA	38.	6 138 826		10-24-2000	Fijioka et al.	
CA	39.	6 143 780		11-07-2000	Brouwer et al.	
CA	40.	6 169 092 B1		01-02-2001	Braunlich et al.	
CA	41.	6 174 905 B1		01-16-2001	Suzuki et al.	
CA	42.	6 177 074		01-23-2001	Glue et al.	
CA	43.	6 316 492		11-13-2001	Young et al.	
CA	44.	6 399 657 B1		06-04-2002	Braunlich et al.	
CA	45.	6 407 246		06-18-2002	Uckun et al.	
CA	46.	6 420 396 B1		07-16-2002	Albers et al.	
CA	47.	6 440 985		08-27-2002	Bailey et al.	
CA	48.	6 528 528 B2		03-04-2003	Connor et al.	
CA	49.	6 610 715 B1		08-26-2003	Youn et al.	
CA	50.	6 677 360 B1		01-13-2004	Albers et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cita No.	Document Number			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ^a
		Office ^c	Number	Kind ^b (if known)				
CA	51.	WO	99/59586 A1		11-25-1999	Regents of the Univ. of Calif		
CA	52.	WO	00/35864 A1		08-22-2000	Bayer Aktiengesellschaft		
CA	53.	WO	2003/037869 A1		05-08-2003	Janssen Pharmaceutica		
CA	54.	WO	2003/097604 A1		11-27-2003	Bayer Cropscience GmbH		
CA	55.	WO	2003/097605 A1		11-27-2003	Bayer Cropscience GmbH		
CA	56.	WO	2003/099812 A1		12-04-2003	Pierre Fabre Medicament	Transl. of claims only	X
CA	57.	WO	2004/020416 A2		03-11-2004	Bayer Cropscience GmbH	Transl. of claims only	X

Examiner
Signature

AULAKH

Date
Considered

3/27/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP-609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/716,175
				Filing Date	11/18/2003
				First Named Inventor	Dawei Chen et al.
				Art Unit	1614
				Examiner Name	C. Aulakh
Sheet	3	of	6	Attorney Docket Number	API-0002

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code* (if known)			
CA	58.	6 677 372	B1	01-13-2004	Braulich et al.	
CA	59.	6 713 502	B2	03-30-2004	Dhanak et al.	
CA	60.	6 727 267	B2	04-27-2004	Jaen et al.	
CA	61.	6 736 336		05-18-2004	Wong	
CA	62.	6 770 666		08-03-2004	Hashimoto et al.	
CA	63.	6 780 873	B1	08-24-2004	Crooks et al.	
CA	64.	6 864 289	B1	03-08-2005	Tohnishi et al.	
CA	65.	2002/0099210	A1	07-25-2002	Alexander et al.	
CA	66.	2003/0109578	A1	06-12-2003	Braunlich et al.	
CA	67.	2003/0195231		10-16-2003	Takemoto et al.	
CA	68.	2004/0009982	A1	01-15-2004	Tohnishi et al.	
CA	69.	2004/0029877	A1	02-12-2004	Crooks et al.	
CA	70.	2004/0034041		02-19-2004	Dhanak et al.	
CA	71.	2004/0082635		04-29-2004	Hashimoto et al.	
CA	72.	2004/0097438		05-20-2004	Hashimoto et al.	
CA	73.	2004/0132727	A1	07-08-2004	Sakai et al.	
CA	74.	2004/0147535		01-22-2004	Crooks et al.	
CA	75.	2004/0147569		07-29-2004	Suzuki et al.	
CA	76.	2004/0147741		07-29-2004	Sundermann et al.	
CA	77.	2004/0162287	A1	08-19-2004	Sundermann et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Document Number			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ^o
		Office*	Number*	Kind* (if known)				

Examiner Signature	<i>AULAKH</i>	Date Considered	3/27/06
--------------------	---------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP-809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	11/015,300
				Filing Date	12/17/2004
				First Named Inventor	Dawei Chen et al.
				Art Unit	1814
				Examiner Name	C. Aulakh
				Attorney Docket Number	API-0002
Sheet	4	of	6		

[illegible][illegible]

Examiner Signature	ALLACH	Date Considered	3/27/06
-----------------------	--------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP-809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard SI. 16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-1449		Attorney's Docket Number API-0002	Serial Number 10/716,175
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <u>LIST OF ITEMS</u> (Use several sheets if necessary)		Name of Applicant Dawei Chen et al	
		Filing Date 11/18/2003	Group 1614
OTHER INFORMATION (including author, title, date, pertinent)			Translati on provided
CA	Alter, H.J. and Seeff, L.B., "Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: a Perspective on Long-Term Outcome," <i>Seminars in Liver Disease</i> , (2000) 20(1): 17-35.		
CA	Baltabaev, U.A. et al., "Synthesis of the Nicotinoylthioureas Compounds," <i>Azerbaidzhanskii Kim. Zhur.</i> , (2000) 4: 97-99		yes
CA	Baltabaev, U.A. et al., "Antiinflammatory Activity Of New Aryl- and Aroylthioureas," <i>Pharmaceutical Chemistry Journal</i> (2002) 36(2): 24-26.		
CA	Bartenschlager, R. "The NS3/4A Proteinase of the Hepatitis C Virus: Unravelling Structure and Function of an Unusual Enzyme and a Prime Target for Antiviral Therapy," <i>Journal of Viral Hepatitis</i> , (1999) 6:165-181.		
CA	Bressanelli, S. et al., "Crystal structure of the RNA-Dependent RNA Polymerase of Hepatitis C Virus," <i>Proceedings of the National Academy of Sciences, USA</i> , (1999) 96:13034-13039.		
CA	De Francesco, R. et al., "The Hepatitis C Virus NS3 Proteinase: Structure and Function of a Zinc-Containing Serine Proteinase," <i>Therapies for Viral Hepatitis</i> , (1998), pp. 235-245. Edited by R. F. Schinazi, J.-P. Sommadossi & H. C. Thomas. London: International Medical Press.		
CA	Douglass, I.B. and Forman, L.E. "Nicotinyl Isothiocyanate And Some Of Its Derivatives," <i>Journal of the American Chemical Society</i> (1934) 56(7): 1609		
CA	Du, X. et al., "Aryl Ureas Represent a New Class of Anti-Trypanosomal Agents," <i>Chemistry & Biology</i> (2000) 7(9): 733-742.		
CA	Esteban, J.I. et al., "The Clinical Picture of Acute and Chronic Hepatitis C," <i>Curr. Stud. Hematol. Blood Transf., Hepatitis C Virus</i> , (1998) 62: 102-118. Edited by W. Reesink. Basel, Switzerland: Karger.		
CA	Fukushi, S. et al., "Complete 5' Noncoding Region is Necessary for the Efficient Internal Initiation of Hepatitis C Virus RNA," <i>Biochemical and Biophysical Research Communications</i> , (1994) 199: 425-432.		
CA	Fukushi, S. et al., "The Sequence Element of the Internal Ribosome Entry Site and a 25-Kilodalton Cellular Protein Contribute to Efficient Internal Initiation of Translation of Hepatitis C Virus RNA," <i>Journal of Virology</i> , (1997) 71:1662-1666.		
CA	Goerdeler, J. and Jonas, K. "Uber Thioacyl-isocyanate, V. Substituierte Thiazolin-dione-(4.5) und ihre Thermische Spaltung in Isocyanate und Senfole," <i>Chemische Berichte</i> (1966) 99(11): 3572-3581.		yes
CA	Goerdeler, J. and Wobig, D. "Das dualistische Verhalten von Carbamoyl-isothiocyanaten, I," <i>Liebigs Annalen Der Chem</i> (1970) 731: 120-141		yes
CA	Gwack, Y. et al., "Characterization of RNA Binding Activity and RNA Helicase Activity of the Hepatitis C Virus NS3 Protein," <i>Biochemical and Biophysical Research Communications</i> (1996) 225: 654-659.		
CA	Honda, M. et al., "Structural Requirements for Initiation of Translation by Internal Ribosome Entry within Genome-length Hepatitis C Virus RNA," <i>Virology</i> , (1996) 222: 31-42.		
CA	Iacovacci, S. et al., "Replication and mMtultiplication of Hepatitis C Virus Genome in Human Foetal Liver Cells," <i>Research in Virology</i> , (1993) 144: 275-279.		
CA	Khromykh, A.A. and Westaway, E.G., "Subgenomic Replicons of the Flavivirus Kunjin: Construction and Applications," <i>Journal of Virology</i> , (1997) 71: 1497-1505.		
CA	Kim, J.L. et al., "Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor Peptide," <i>Cell</i> , (1996) 87: 343-355.		
CA	Kim, J.L. et al., "Hepatitis C Virus NS3 RNA Helicase Domain with a Bound Oligonucleotide: the Crystal Structure Orovides Insights into the Mode of Unwinding," <i>Structure</i> (1998) 6(1): 89-100.		

EXAMINER <i>ALU LAKH</i>	DATE CONSIDERED <i>3/27/06</i>
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.	

PTO-1449		Attorney's Docket Number API-0002	Serial Number 10/716,175
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Name of Applicant Dawei Chen et al	
LIST OF ITEMS		Filing Date 11/18/2003	Group 1614
(Use several sheets if necessary)			
OTHER INFORMATION (including author, title, date, pertinent)			Translati on provided
CA	Koscik, D. et al., "New Synthesis of 2-Amino-4-oxopyrido[3,2-e]-1,3-thiazines and 1-Alkyl(aryl)pyrido[3,2-e]-2-thiouracils," <i>Collection Czechoslovak Chem. Comm.</i> (1983) 48: 3315-3328.		
CA	Lavanchy, D. et al., "Global Surveillance and Control of Hepatitis C," <i>Journal of Viral Hepatitis</i> (1999) 6: 35-47.		
CA	Lesburg, C.A. et al., "Crystal Structure of the RNA-Dependent RNA Polymerase from Hepatitis C Virus Reveals a Fully Encircled Active Site," <i>Nature Structural Biology</i> , (1999) 6: 937-943.		
CA	Liang, T.J. et al., "Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C," <i>Annals of Internal Medicine</i> (2000) 132: 296-305.		
CA	Lohmann, V. et al., "Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line," <i>Science</i> (1999) 285: 110-113.		
CA	Love, R.A. et al., "The Crystal Structure of Hepatitis C Virus NS3 proteinase reveals a trypsin-like fold and a Structural zinc binding site," <i>Cell</i> (1996) 87:331-342.		
CA	Manns, M.P. et al., "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic Hepatitis C: a randomised trial," <i>Lancet</i> (2001):358:958-965.		
CA	McHutchison, J.G. et al., "Interferon Alfa-2b Alone or in Combination with fRibavirin as Initial Treatment for Chronic Hepatitis C," <i>New England Journal of Medicine</i> (1998) 339(21):1485-1492.		
CA	Mitin, N.I. et al., "Effect of Adamantyl-Containing Compounds on the viruses of False Rabies and Bird Flu", <i>Fiziologicheski Aktivnye Veshchestva</i> (1977) 9: 31-35		yes
CA	Moriya, K. et al., "The Core Protein of Hepatitis C Virus Induces Hepatocellular Carcinoma in Transgenic Mice," <i>Nature Medicine</i> (1998) 4:1065-1067.		
CA	Neumann, A.U. et al., "Hepatitis C Viral Dynamics In Vivo and the Antiviral Efficacy of Interferon-Alpha Therapy," <i>Science</i> , (1998) 282: 103-107.		
CA	Nogrady, T. <i>Medicinal Chemistry A Biochemical Approach</i> , (1985) Oxford University Press, New York, pages 388-392		
CA	Patel, N.B. and Bhagat, P.R. "2-[4]-(p-Acetamidophenylcarbonyl) Piperazin-1"-yl]-3-(N-Aryl-Thioureidocarbonyl) Pyridines As Antibacterial Agents," <i>Indian Journal of Heterocyclic Chemistry</i> (2002) 12: 83-84.		
CA	Patel, N.B. and Bhagat, P.R. "Antibacterial Study of 2-(p-Tolyl Sulfonamido)-3-(N-Arylthioureido Carbonyl) Pyridine Derivatives" <i>Oriental Journal of Chemistry</i> (2002) 18(3): 551-554.		
CA	Praceus, Chr. et al., "Inhibition of Vaccinia Virus In Vitro By Substituted Monophenylthioureas," <i>Naturwissenschaften</i> (1964) 51(4): 94-95.		yes
CA	Reynaud, P. et al., "P-alcoxy Benzoyl-1 p-Alcoxyphenyl-3 thioureas: Their Activity "In Vitro" and "In Vivo" on the H ₃₇ RV of the Tubercular Bacillus," <i>Chimie Therapeutique</i> (1966) 7: 421-424. (machine translation)		yes
CA	Santolini, E. et al., "Biosynthesis and Biochemical Properties of the Hepatitis C Virus Core Protein," <i>Journal of Virology</i> (1994) 68: 3631-3641.		
CA	Schuster, G. "Structurally Dependent Effects of Substituted Thioureas on the Concentration of Potato Virus X in Nicotiana tabacum L.," <i>Zbl. Bakt. II, Dep.</i> (1978) 133(7-8): 686-689.		yes
CA	Simmonds, P. et al., "Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region," <i>Journal of General Virology</i> (1993) 74:2391-2399.		
CA	Stempniak, M. et al., "The NS3 proteinase domain of hepatitis C virus is a zinc-containing enzyme," <i>Journal of Virology</i> (1997) 71:2881-2886.		
CA	Tanaka, T. et al., "Structure of the 3' terminus of the hepatitis C virus genome," <i>Journal of Virology</i> (1996) 70:3307-3312.		
CA	Tsukiyama-Kohara, K. et al., "Internal ribosome entry site within hepatitis C virus RNA," <i>Journal of Virology</i> , (1992) 66:1476-1483.		
EXAMINER AW/AXH		DATE CONSIDERED 3/27/06	
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.			

